期刊
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
卷 128, 期 4, 页码 875-879出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13813455.2020.1734842
关键词
Alzheimer's disease; microRNA; biomarker; serum
资金
- Research & Technology Deputy, Hamadan University of Medical Sciences [9603302132]
miR-106b may be a promising serum biomarker for early diagnosis of Alzheimer's disease.
Analysis of miRNAs has a strong potential for the identification of novel prognostic or predictive biomarkers in the serum of AD patients. In this study, we investigated the serum levels of miR-106b as a diagnostic biomarker for AD and evaluate its predictive value for therapeutic response to the drug rivastigmine. Patients were divided into either responding (n = 33) or non-responding (n = 23) groups according to rivastigmine treatment and to Mini-Mental State Exam score. The serum concentrations of miR-106b were measured with real-time PCR. Here, we found that miR-106b was significantly down-regulated in the serum samples of AD patients compared with those of controls (p < .001). ROC results showed a specificity of 62% and a sensitivity of 94%. The serum values of miR-106b tended to be positively associated with the therapeutic response but were not significant (p = .15). Taken together, detection of serum miR-106b might be a promising serum biomarker for early diagnosis of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据